baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

ABBVIE/ US00287Y1091 /

- -	Chg. -	Volume	Bid-	Ask-	Market Capitalization	Dividend Y.	P/E Ratio
-EUR	-	- Turnover: -	-Bid Size: -	-Ask Size: -	328.94 bill.EUR	-	-

GlobeNewswire 08-29 Great Place To Work Announces the 2024 Best Workplaces in Asia Representing 6.9 Million Employee Exp...

GlobeNewswire 08-28 Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference

GlobeNewswire 08-28 Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568

GlobeNewswire 08-23 NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Confere...

GlobeNewswire 08-19 TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults wit...

GlobeNewswire 08-15 Soleno Therapeutics Announces Updates to its Board of Directors

GlobeNewswire 08-09 Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2...

GlobeNewswire 08-08 CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 08-08 Aligos Therapeutics Strengthens Board with Two New Independent Directors

GlobeNewswire 08-08 Genmab Announces Financial Results for the First Half of 2024

GlobeNewswire 08-08 Genmab Updates 2024 Financial Guidance

GlobeNewswire 08-08 Royalty Pharma Reports Second Quarter 2024 Results

GlobeNewswire 08-07 Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 08-01 Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies i...

GlobeNewswire 08-01 CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024

GlobeNewswire 08-01 NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer

GlobeNewswire 08-01 Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc.

GlobeNewswire 07-31 Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors

GlobeNewswire 07-31 Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV111, a CD19 Directed in situ CAR...

GlobeNewswire 07-30 Montara Therapeutics Closes $8 Million Seed Round Led by SV Health Investors’ Dementia Discovery Fun...

GlobeNewswire 07-28 Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzhei...

GlobeNewswire 07-25 Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Tre...

GlobeNewswire 07-24 Emerging Gene Therapies Signal Transformative Shift in Retinal Disorder Treatment, According to Sphe...

GlobeNewswire 07-24 Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

GlobeNewswire 07-24 OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial fo...

ABBVIE/ US00287Y1091 /

If you wish to receive reply to your feedback, please provide your email address.